The Anglo-Swedish pharmaceutical concern AstraZeneca is building a US$1.5 billion manufacturing facility in Tuas South, Singapore. This will create over 800 jobs in engineering, technical services, and supply chain roles, The Business Times reports. Deputy Prime Minister Gan Kim Yong attended the groundbreaking event on November 7. Covering 23 hectares, this will be AstraZeneca’s largest initial investment and its first full-scale production site for antibody drug conjugates (ADCs).
Pam Cheng, AstraZeneca’s executive vice president for global operations and IT, and chief sustainability officer, stated that the facility will be designed to achieve zero carbon emissions from day one of its operations.
The facility, set to open by 2029, will produce ADCs that directly target cancer cells while sparing healthy ones. AstraZeneca’s expansion in Singapore aligns with the country’s goal to become a key hub in the biopharmaceutical industry.
Read more from ScandAsia: AstraZeneca builds 1.5 billion cancer drug factory in Singapore
